45 results on '"Vogelzang, Jayne"'
Search Results
2. The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location
3. Structural variants shape driver combinations and outcomes in pediatric high-grade glioma
4. Early EEG hyperexcitability is associated with decreased survival in newly diagnosed IDH-wildtype glioma
5. PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation
6. TMIC-11. SPATIAL PROFILING OF TUMOR VASCULATURE AT AUTOPSY IN BRAINSTEM GLIOMAS
7. DDDR-09. FUNCTIONAL GENOMICS AND CHEMOTHERAPY RESISTANCE SCREENING IDENTIFIES BIOMARKERS AND TARGETABLE MECHANISMS OF CCNU RESISTANCE IN GLIOMAS
8. Correction to: Early EEG hyperexcitability is associated with decreased survival in newly diagnosed IDH-wildtype glioma
9. Glioma genetic profiles associated with electrophysiologic hyperexcitability.
10. Glioma genetic profiles associated with electrophysiologic hyperexcitability
11. Molecular Landscape and Contemporary Prognostic Signatures of Gliomas
12. Supplementary Figure 6 from ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
13. Data from ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
14. Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma
15. Abstract 1201: ALK amplification and rearrangements are recurrent targetable events in congenital and adult glioblastoma
16. Abstract 3562: Dissecting mechanisms underlying FOXR2-mediated gliomagenesis in diffuse midline gliomas
17. Supplementary Figure 5 from ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
18. Supplementary Figure 4 from ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
19. Supplementary Figure 3 from ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
20. Supplementary Tables 1-8 from ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
21. Supplementary Table from FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits
22. Supplementary Figure from FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits
23. Data from FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits
24. ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
25. Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment
26. Clinical Trial Enrollment Among Adolescent and Young Adults with Primary Central Nervous System Tumors Treated at the Dana-Farber Cancer Institute
27. QLTI-24. ANALYSIS OF DISPARITIES IN PEDIATRIC BRAIN TUMOR BANK ENROLLMENT AS FOUNDATION FOR QUALITY IMPROVEMENT INITIATIVES AT DANA-FARBER CANCER INSTITUTE/BOSTON CHILDREN’S CANCER AND BLOOD DISORDERS CENTER
28. PATH-15. THE PROGNOSTIC IMPLICATION OF MGMT PROMOTER METHYLATION IN IDH-MUTANT GLIOMAS
29. FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits
30. Abstract 5730: FOXR2 is an oncogenic driver across adult and pediatric cancers
31. HGG-60. Structural variants shape driver combinations and outcomes in pediatric high-grade glioma
32. RARE-22 Characterizing the landscape of structural variants in adamantinomatous craniopharyngioma
33. DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers
34. LGG-32. Integrated biologic, radiologic and clinical analysis of pediatric low-grade gliomas during and after targeted therapy treatment
35. Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics
36. Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics.
37. Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment.
38. LGG-03. LONG-TERM FOLLOW UP OF TARGETED THERAPY IN PEDIATRIC LOW-GRADE GLIOMAS: THE DANA-FARBER/BOSTON CHILDREN’S EXPERIENCE
39. Structural variants shape driver combinations and outcomes in pediatric high-grade glioma
40. EPID-11. A MULTI-INSTITUTIONAL COMPARATIVE ANALYSIS OF THE CLINICAL, GENOMIC, AND SURVIVAL CHARACTERISTICS OF PEDIATRIC, YOUNG ADULT AND OLDER ADULT PATIENTS WITH IDH-MUTANT GLIOMA
41. PATH-03. CLINICAL UTILITY OF NEXT GENERATION SEQUENCING IN IDH-WILDTYPE GLIOBLASTOMA: THE DANA-FARBER CANCER INSTITUTE EXPERIENCE
42. Contemporary Prognostic Signatures and Refined Risk Stratification of Gliomas: An Analysis of 4,400 Tumors.
43. A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients.
44. Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma.
45. Glioma genetic profiles associated with electrophysiologic hyperexcitability.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.